Table 2.
Effect of ginger on degenerative disease (in vivo studies).
Related Disease | Constituent | Effects | References |
---|---|---|---|
Alzheimer's disease | Ginger root extract | (i) Improved learning and memory (ii) Increased the number of Nissl bodies and neurons (iii) Increased the activation of SOD and CAT (iv) Decreased the levels of MDA, NF-κB, and interleukin-1 (IL-1) |
Zeng et al. [103] |
Aqueous ginger infusion | (i) Improved the activity and level of acetylcholine (ii) Improved T-maze test results and reduced acetylcholinesterase activity (iii) Induced the disappearance of amyloid plaques |
Karam et al. [104] | |
| |||
Parkinson's disease | 6-Shogaol | (i) Reduced astrogliosis and microgliosis in the brain (ii) Enhanced the expression of nerve growth factor (NGF) level and synaptic molecules (iii) Inhibited the inflammatory response |
Moon et al. [105] |
6-Shogaol | (i) Improved the formation of synapses in the brain (ii) Inhibited components of the inflammatory pathway such as TNF-α, NO, COX-2, and inducible nitric oxide synthase (iNOS) |
Park et al. [106] | |
| |||
Type 2 diabetes mellitus | Fresh ginger sample | (i) Exhibited inhibitory activities against α-amylase and α-glucosidase (ii) Inhibited ACE activity |
Akinyemi et al. [109] |
| |||
Cardiovascular disease | Ginger extract | (i) Reduced infarct size (ii) Reduced total cholesterol serum |
Rouhi-Boroujeni et al. [113] |
Ethanolic ginger extract | (i) Decreased the development of atherosclerotic lesions (ii) Reduced plasma levels, LDL cholesterol levels, LDL atherogenic modifications, and the oxidative response of macrophages |
Fuhrman et al. [114] | |
6-Gingerol | (i) Reduced atherosclerotic lesions in arteries (ii) Reversed the expression of inflammatory cytokines and lipids |
Wang et al. [115] | |
Dried ginger powder | (i) Decreased lipid levels and blood pressure | Sanghal et al. [117] | |
Aqueous ginger extract | (i) Inhibited ACE activity (ii) Prevented lipid peroxidation in the heart |
Akinyemi et al. [83] | |
Fresh ginger sample | (i) Inhibited ACE activity | Akinyemi et al. [109] |